An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease - Regional Cancer Care Associates LLC

Clinical Trials

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Type of Cancer

Warning: implode(): Invalid arguments passed in /home/region33/public_html/wp-content/themes/regionalcancercenter/single-clinical-trials.php on line 42
Locations
Sponsor
Novartis
Protocol Number
CLEE11A2404 CompLEEment-1
Cancer Diagnosis
To Learn More Call
201-510-0910